Business Context and Reporting Period
Company: eXoZymes Inc. (Nasdaq: EXOZ)
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2026
Event: Closing of an underwritten public offering and partial exercise of the over-allotment option.
Key Financial Metrics
Capital Raised: Approximately $5.95 million in gross proceeds (inclusive of over-allotment).
Offering Structure: Units consisting of two shares of Common Stock and one Warrant.
Offering Price: $18.00 per unit.
Shares Issued: 661,150 total shares (592,270 initial + 68,880 over-allotment).
Warrants Issued: 330,575 total warrants (296,135 initial + 34,440 over-allotment).
Net Proceeds: Not specified in this filing; gross proceeds are before underwriting discounts, commissions, and estimated expenses.
Material Changes
- Equity Dilution: The company issued 661,150 new shares of common stock and 330,575 warrants, increasing the outstanding share count and potential future dilution.
- Liquidity Event: The offering closed on June 9, 2026, with the over-allotment option partially exercised on June 17, 2026, providing immediate cash inflow.
- Underwriter Action: MDB Capital exercised a portion of its 45-day over-allotment option, purchasing 34,440 units (representing 38.8% of the total option size).
Outlook, Management Commentary, and Risks
Use of Proceeds: Management plans to utilize net proceeds to support development and commercialization of N-trans-caffeoyltyramine (NCT), advance additional product opportunities, fund research and development, and for working capital and general corporate purposes.
Regulatory Status: The offering was conducted pursuant to an effective shelf registration statement (Form S-3) declared effective on January 23, 2026.
Risks/Contingencies: The filing notes that the description of the Underwriting and Warrant Agent Agreements is qualified by the full text of those documents. No specific financial risks or contingencies regarding the company's operations were detailed in this specific 8-K text beyond standard offering terms.
Investor Verification Checklist
- Verify the exact net proceeds after deducting underwriting discounts and commissions, as only gross proceeds ($5.95 million) are stated.
- Review the full text of the Underwriting Agreement (Exhibit 10.1) and Warrant Agent Agreement (Exhibit 10.2) for specific warrant exercise terms, expiration dates, and strike prices.
- Confirm the updated total share count and fully diluted share count post-offering.
- Assess the company's current cash runway and burn rate to evaluate if the $5.95 million gross proceeds are sufficient to reach the next major milestone for NCT development.